CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
MDA2014-04-01 CP-CTNet_CLO-MD Anderson Alternative Dosing of Exemestane in Postmenopausal Women with Stage 0-II ER-Positive Breast Cancer: a Randomized Presurgical Trial Cancer Prevention and Control CIRB
MDA2014-04-02 CP-CTNet_CLO-MD Anderson VADIS Trial: Phase II trial of Nelipepimut-S Peptide Vaccine in Women with DCIS of the Breast Cancer Prevention and Control CIRB
MDA2016-07-02 CP-CTNet_CLO-MD Anderson A Randomized, Double-blind, Placebo-controlled Study of 4-hydroxytamoxifen Topical Gel in Women with Mammographically Dense Breast Cancer Prevention and Control CIRB
MDA2016-08-02 CP-CTNet_CLO-MD Anderson A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer Cancer Prevention and Control CIRB
MDA2017-09-03 CP-CTNet_CLO-MD Anderson Pilot Study of Denosumab in BRCA1/2 Mutation Carriers scheduled for Risk-reducing Salpingooophorectomy Cancer Prevention and Control CIRB
MDA21-06-01 CP-CTNet_CLO-MD Anderson A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome Cancer Prevention and Control CIRB
MM1MDS-A01 Alliance A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study Adult CIRB - Late Phase Emphasis
MM1OA-EA02 ECOG-ACRIN A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial Adult CIRB - Late Phase Emphasis
MM1OA-S03 SWOG Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy Adult CIRB - Late Phase Emphasis
MM1YA-S01 SWOG A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial Adult CIRB - Late Phase Emphasis